Literature DB >> 16822228

Case studies in swelling polymeric gastric retentive tablets.

Bret Berner1, Verne E Cowles.   

Abstract

Swelling tablets administered in the fed state have been shown to provide therapeutic advantages in two marketed products, with the duration of delivery characterised with respect to food and tablet size. Metformin extended-release tablets are a diffusion-based swelling tablet demonstrating once-daily efficacy with good gastrointestinal solubility. Ciprofloxacin extended-release tablets are based on an erosional matrix that delivers the drug to the upper gastrointestinal tract over 6 h to provide once-daily efficacy with reduced incidences of nausea and diarrhoea. Furosemide extended-release tablets are another example of an erosional matrix designed to deliver furosemide to the duodenum and upper jejunum over 6 h to provide a more gradual diuresis and naturesis compared with the immediate-release product.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16822228     DOI: 10.1517/17425247.3.4.541

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  11 in total

1.  Steady-state pharmacokinetics of gabapentin after administration of a novel gastroretentive extended-release formulation in postmenopausal women with vasomotor symptoms.

Authors:  Verne E Cowles; Toufigh Gordi; Sui Yuen Eddie Hou
Journal:  Clin Drug Investig       Date:  2012-09-01       Impact factor: 2.859

2.  Oral, ultra-long-lasting drug delivery: Application toward malaria elimination goals.

Authors:  Andrew M Bellinger; Mousa Jafari; Tyler M Grant; Shiyi Zhang; Hannah C Slater; Edward A Wenger; Stacy Mo; Young-Ah Lucy Lee; Hormoz Mazdiyasni; Lawrence Kogan; Ross Barman; Cody Cleveland; Lucas Booth; Taylor Bensel; Daniel Minahan; Haley M Hurowitz; Tammy Tai; Johanna Daily; Boris Nikolic; Lowell Wood; Philip A Eckhoff; Robert Langer; Giovanni Traverso
Journal:  Sci Transl Med       Date:  2016-11-16       Impact factor: 17.956

3.  Once-daily gastroretentive gabapentin for the management of postherpetic neuralgia: an update for clinicians.

Authors:  Gordon Irving
Journal:  Ther Adv Chronic Dis       Date:  2012-09       Impact factor: 5.091

Review 4.  Modified-Release Formulations of Second-Generation Antiepileptic Drugs: Pharmacokinetic and Clinical Aspects.

Authors:  Gail D Anderson; Russell P Saneto
Journal:  CNS Drugs       Date:  2015-08       Impact factor: 5.749

5.  Potential role of gabapentin and extended-release gabapentin in the management of menopausal hot flashes.

Authors:  Manisha Yadav; Judith Volkar
Journal:  Int J Gen Med       Date:  2013-08-07

6.  Relationships Among Adverse Events, Disease Characteristics, and Demographics in Treatment of Postherpetic Neuralgia With Gastroretentive Gabapentin.

Authors:  Naum Shaparin; Patricia W Slattum; Iwona Bucior; Srinivas Nalamachu
Journal:  Clin J Pain       Date:  2015-11       Impact factor: 3.442

7.  The Effect of Once-Daily Gabapentin Extended Release Formulation in Patients With Postamputation Pain.

Authors:  Nebojsa Nick Knezevic; Tabish Aijaz; Kenneth D Candido; Svetlana Kovaleva; Alexei Lissounov; Ivana Knezevic
Journal:  Front Pharmacol       Date:  2019-05-15       Impact factor: 5.810

8.  Tolerability and safety of gastroretentive once-daily gabapentin tablets for the treatment of postherpetic neuralgia.

Authors:  Gordon A Irving; Michael Sweeney
Journal:  J Pain Res       Date:  2012-06-25       Impact factor: 3.133

9.  Safety and efficacy of once-daily gastroretentive gabapentin in patients with postherpetic neuralgia aged 75 years and over.

Authors:  Anita Gupta; Sean Li
Journal:  Drugs Aging       Date:  2013-12       Impact factor: 3.923

10.  Pharmacokinetics and bioavailability of oxycodone and acetaminophen following single-dose administration of MNK-795, a dual-layer biphasic IR/ER combination formulation, under fed and fasted conditions.

Authors:  Krishna Devarakonda; Terri Morton; Rachel Margulis; Michael Giuliani; Thomas Barrett
Journal:  Drug Des Devel Ther       Date:  2014-08-19       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.